AR046201A1 - Metodos para preparar derivados 7-(beta-d-ribofuranosilo sustituido en 2'-r1)-4(nr2r3)-5-(etin-1-ilo sustituido)- pirrol[2,3- d]pirimidina - Google Patents
Metodos para preparar derivados 7-(beta-d-ribofuranosilo sustituido en 2'-r1)-4(nr2r3)-5-(etin-1-ilo sustituido)- pirrol[2,3- d]pirimidinaInfo
- Publication number
- AR046201A1 AR046201A1 ARP040103896A ARP040103896A AR046201A1 AR 046201 A1 AR046201 A1 AR 046201A1 AR P040103896 A ARP040103896 A AR P040103896A AR P040103896 A ARP040103896 A AR P040103896A AR 046201 A1 AR046201 A1 AR 046201A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- amino
- hydrogen
- pyrimidine
- alkyl
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- -1 amino, substituted amino, hydroxy Chemical group 0.000 abstract 6
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000004665 trialkylsilyl group Chemical group 0.000 abstract 2
- 150000000841 D-ribofuranose derivatives Chemical class 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un método para preparar 7-(beta-D-ribofuranosilo sustituido en 2´-R1)-4-(NR2R3)-5-(etin-1-il)-pirro[2,3-d]pirimidina de la fórmula (1), donde: R1 se selecciona del grupo formado por alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido; R2 y R3 se seleccionan independientemente entre hidrógeno, alquilo, alquilo sustituido, amino, amino sustituido, hidroxi, alcoxi, alcoxi sustituido, formilo y acilo, y donde R2 y R3, junto con el átomo de nitrógeno unido a los mismos, se unen para formar un anillo heterocíclico o heterocíclico sustituido, con la condición que cuando uno de R2 o R3 es amino, amino sustituido, hidroxi, alcoxi, alcoxi sustituido, entonces el otro es hidrógeno; caracterizado porque dicho método comprende: a) hacer reaccionar al menos un equivalente estequiométrico de 4,5-dihalo-7H-pirro[2,3-d]pirimidina con D-ribofuranosa sustituida en 2-R1 protegida con 1-bromo-3,5-di-O bajo condiciones que permitan el acoplamiento para proveer 7-(beta-D-ribofuranosilo sustituido en 2'-R1 protegido con 3',5'-di-O)-4,5-dihalo-pirrol[2,3-d]pirimidina, donde los grupos halo de 4,5-dihalo son ortogonales entre sí; b) separar los grupos protectores del compuesto preparado previamente en a) para proveer la 7-(beta-D-ribofuranosilo sustituido en 2'-R1)-4,5-dihalo-pirrol[2,3-d]pirimidina; c) aminar selectivamente el grupo 4-halo en dicha 7-(beta-D-ribofuranosilo sustituido en 2'-R1)-4,5-dihalo-pirrol[2,3- d]pirimidina para proveer un sustituyente 4-amino opcionalmente sustituido de la fórmula NR2R3, donde R2 y R3 son como se definieron previamente; d) hacer reaccionar la 7-(beta-ribofuranosilo sustituido en 2'-R1)-4-(NR2R3)-5-halo-pirrol[2,3- d]pirimidina con un compuesto acetileno monoprotegido bajo condiciones de acoplamiento para proveer la 7-(beta-D-ribofuranosilo sustituido en 2'-R1)-4-(NR2R3)-5-(etin-1-ilo protegido)-pirrol[2,3-d]pirimidina; y e) separar dicho grupo protector de dicha 5-(etin-1-ilo protegido) para proveer la 7-(beta-D-ribofuranosilo sustituido en 2'-R1)-4-(NR2R3)-5-(etin-1-il)-pirrol[2,3-d]pirimidina. Reivindicación 52: Un compuesto, caracterizado porque es de la fórmula (2), donde: R7 se selecciona del grupo formado por hidrógeno, trialquilsililo, fenilo, fenilo sustituido, alcoxialquilo, heteroarilo, heteroarilo sustituido, -C(O)OR4, donde R4 es hidrógeno o alquilo, -C(O)NR5R6, donde R5 y R6 se seleccionan independientemente del grupo formado por hidrógeno, alquilo, alquilo sustituido, amino, amino sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclos y heterociclos sustituido, siempre que solamente uno de R5 y R6 sea amino o amino sustituido, y además donde R5 y R6, junto con el átomo de nitrógeno unido a los mismos, forman un heterociclo o heterociclo sustituido; y Pg3 es un grupo protector de amino o hidrógeno. Reivindicación 54: Un compuesto, caracterizado porque es de la fórmula (3), donde: R7 se selecciona del grupo formado por hidrógeno, trialquilsililo, fenilo, fenilo sustituido, alcoxialquilo, heteroarilo, heteroarilo sustituido, -C(O)OR4, donde R4 es hidrógeno o alquilo, -C(O)NR5R6, donde R5 y R6 se seleccionan independientemente del grupo formado por hidrógeno, alquilo, alquilo sustituido, amino, amino sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterociclos y heterociclos sustituido, siempre que solamente uno de R5 y R6 sea amino o amino sustituido, y además donde R5 y R6, junto con el átomo de nitrógeno unido a los mismos, forman un heterociclo o heterociclo sustituido; y Pg3 es un grupo protector de amino o hidrógeno.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51515303P | 2003-10-27 | 2003-10-27 | |
| US10/861,090 US7202223B2 (en) | 2003-10-27 | 2004-06-04 | Nucleoside compounds for treating viral infections |
| US10/861,311 US7144868B2 (en) | 2003-10-27 | 2004-06-04 | Nucleoside compounds for treating viral infections |
| US60281504P | 2004-08-18 | 2004-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046201A1 true AR046201A1 (es) | 2005-11-30 |
Family
ID=34577847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103896A AR046201A1 (es) | 2003-10-27 | 2004-10-26 | Metodos para preparar derivados 7-(beta-d-ribofuranosilo sustituido en 2'-r1)-4(nr2r3)-5-(etin-1-ilo sustituido)- pirrol[2,3- d]pirimidina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7169918B2 (es) |
| EP (1) | EP1682564A1 (es) |
| AR (1) | AR046201A1 (es) |
| CA (1) | CA2543116A1 (es) |
| SV (1) | SV2005001918A (es) |
| UY (1) | UY28582A1 (es) |
| WO (1) | WO2005044835A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084157A2 (en) * | 2005-03-23 | 2007-07-26 | Genelabs Technologies, Inc. | Nucleoside prodrugs for treating viral infections |
| TW200720285A (en) * | 2005-04-25 | 2007-06-01 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| CA2630271C (en) | 2005-11-17 | 2014-04-08 | Osi Pharmaceuticals, Inc. | Fused bicyclic mtor inhibitors |
| WO2007087395A2 (en) * | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| EP2307434B1 (en) * | 2008-07-02 | 2014-02-12 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| JP5520961B2 (ja) | 2008-11-28 | 2014-06-11 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための方法 |
| JP5721275B2 (ja) | 2009-04-22 | 2015-05-20 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． | 治療的使用のための新規７−デアザプリンヌクレオシド |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| ES2646019T3 (es) | 2013-05-14 | 2017-12-11 | Nerviano Medical Sciences S.R.L. | Derivados de 6-amino-7-deaza-purina, proceso para su preparación y su uso como inhibidores de cinasa |
| CZ305466B6 (cs) * | 2013-11-04 | 2015-10-14 | Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. | Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití |
| TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| RS65988B1 (sr) | 2016-04-04 | 2024-10-31 | Loxo Oncology Inc | Postupak lečenja pedijatrijskih karcinoma |
| HUE068971T2 (hu) | 2016-04-04 | 2025-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei |
| SI3458456T1 (sl) | 2016-05-18 | 2021-04-30 | Loxo Oncology, Inc. | Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US72788A (en) * | 1867-12-31 | Charles d | ||
| US96981A (en) * | 1869-11-16 | Improvement in buckles for clothinc | ||
| US67901A (en) * | 1867-08-20 | Washinoton | ||
| US14108A (en) * | 1856-01-15 | Jambs mcnab and adam carr | ||
| US35077A (en) * | 1862-04-29 | Improvement in pumps | ||
| US14957A (en) * | 1856-05-27 | Improved guard for circular saws | ||
| US153744A (en) * | 1874-08-04 | Improvement in permutation-locks | ||
| US4140851A (en) * | 1977-11-21 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides |
| JPS61229897A (ja) | 1985-04-05 | 1986-10-14 | Nippon Zoki Pharmaceut Co Ltd | 新規ヌクレオシド化合物 |
| US6211158B1 (en) * | 1987-04-10 | 2001-04-03 | Roche Diagnostics Gmbh | Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents |
| US4892865A (en) * | 1987-12-01 | 1990-01-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents |
| US4968686A (en) * | 1988-04-08 | 1990-11-06 | The Regents Of The University Of Michigan | Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents |
| US4927830A (en) * | 1988-04-08 | 1990-05-22 | The Regents Of The University Of Michigan | Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents |
| US5824796A (en) * | 1988-09-28 | 1998-10-20 | Epoch Pharmaceuticals, Inc. | Cross-linking oligonucleotides |
| US5763597A (en) * | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | Orally active adenosine kinase inhibitors |
| US5248775A (en) * | 1989-12-11 | 1993-09-28 | The Trustees Of Princeton University | Pyrrolo(2,3-d)pyrimidines |
| US4996206A (en) * | 1989-12-11 | 1991-02-26 | The Trustees Of Princeton University | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives |
| WO1991010671A1 (en) | 1990-01-11 | 1991-07-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for detecting and modulating rna activity and gene expression |
| US5681941A (en) * | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| ATE244259T1 (de) * | 1992-02-12 | 2003-07-15 | Chromagen Inc | Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen |
| CA2154681A1 (en) | 1993-02-03 | 1994-08-18 | Mark David Erion | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
| EP0695306A1 (en) | 1993-04-19 | 1996-02-07 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| CA2171868A1 (en) | 1993-09-17 | 1995-03-23 | Petr Alexander | Method for dosing therapeutic compounds |
| EP0679657B1 (de) * | 1994-04-27 | 2003-07-09 | Novartis AG | Nukleoside und Oligonukleotide mit 2'-Ethergruppen |
| US6150510A (en) * | 1995-11-06 | 2000-11-21 | Aventis Pharma Deutschland Gmbh | Modified oligonucleotides, their preparation and their use |
| DE4438918A1 (de) * | 1994-11-04 | 1996-05-09 | Hoechst Ag | Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US6004939A (en) * | 1995-07-06 | 1999-12-21 | Ctrc Research Foundation Board Of Regents | Methods for modulation and inhibition of telomerase |
| WO1997002279A1 (en) * | 1995-07-06 | 1997-01-23 | Ctrc Research Foundation | Methods and compositions for modulation and inhibition of telomerase |
| FR2750435B1 (fr) | 1996-06-27 | 1998-08-28 | Appligene Oncor | Procede de formation de complexes d'hybridation dont la stabilite depend peu de la composition en base des deux molecules d'acides nucleiques hybridees |
| CA2326535A1 (en) * | 1998-03-27 | 1999-10-07 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| PT1087970E (pt) * | 1998-06-19 | 2004-06-30 | Pfizer Prod Inc | Compostos pirrolo¬2,3-d|pirimidina |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| EP1138689A1 (en) | 2000-03-28 | 2001-10-04 | Roche Diagnostics GmbH | N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| CN1267446C (zh) * | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
| US7049303B2 (en) * | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
| WO2003051899A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| WO2003055896A2 (en) | 2001-12-21 | 2003-07-10 | Micrologix Biotech Inc. | Anti-viral 7-deaza l-nucleosides |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| WO2003068244A1 (en) | 2002-02-13 | 2003-08-21 | Merck & Co., Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
| US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
| US20040014108A1 (en) | 2002-05-24 | 2004-01-22 | Eldrup Anne B. | Oligonucleotides having modified nucleoside units |
| AU2003251424A1 (en) * | 2002-06-07 | 2003-12-22 | The Regents Of The University Of California | Electrochemical detection of single nucleotide polymorphisms (snps) |
| WO2004007512A2 (en) | 2002-07-16 | 2004-01-22 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| AU2003254657A1 (en) | 2002-07-25 | 2004-02-16 | Micrologix Biotech Inc. | Anti-viral 7-deaza d-nucleosides and uses thereof |
| NZ538457A (en) * | 2002-09-30 | 2008-04-30 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
| US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| WO2004043978A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
-
2004
- 2004-10-20 CA CA002543116A patent/CA2543116A1/en not_active Abandoned
- 2004-10-20 EP EP04795860A patent/EP1682564A1/en not_active Withdrawn
- 2004-10-20 WO PCT/US2004/034756 patent/WO2005044835A1/en not_active Ceased
- 2004-10-20 US US10/970,641 patent/US7169918B2/en not_active Expired - Fee Related
- 2004-10-26 AR ARP040103896A patent/AR046201A1/es unknown
- 2004-10-26 UY UY28582A patent/UY28582A1/es not_active Application Discontinuation
- 2004-10-27 SV SV2004001918A patent/SV2005001918A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050215510A1 (en) | 2005-09-29 |
| SV2005001918A (es) | 2005-04-18 |
| EP1682564A1 (en) | 2006-07-26 |
| UY28582A1 (es) | 2005-05-31 |
| US7169918B2 (en) | 2007-01-30 |
| CA2543116A1 (en) | 2005-05-19 |
| WO2005044835A1 (en) | 2005-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046201A1 (es) | Metodos para preparar derivados 7-(beta-d-ribofuranosilo sustituido en 2'-r1)-4(nr2r3)-5-(etin-1-ilo sustituido)- pirrol[2,3- d]pirimidina | |
| AR065985A1 (es) | Derivados de arilisoxazolina,composiciones que los contienen y usos de los mismos como agentes insecticidas y acaricidas. | |
| RU2017123114A (ru) | 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов | |
| ES2531256T3 (es) | Amidas fungicidas | |
| CO6251317A2 (es) | Procedimiento para sintetizar sal diclorhidrato de ((1s)-1-(((2s) sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil | |
| PE20010736A1 (es) | PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
| AR063213A1 (es) | Amidas azociclicas fungicidas, composiciones fungicidas que las comprenden y su empleo en un metodo para controlar enfermedades en las plantas causadas por patogenos fungicos de la clase de los oomycetes. | |
| PE20080403A1 (es) | Derivados heterociclicos fusionados y metodos de uso | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| AR036779A1 (es) | 7-aza[2.2.1]bicicloheptanos sustituidos, su uso para el tratamiento de enfermedades donde un mamifero recibe alivio sintomatico de un agonista de acetilcolina a7 nicotinico y composiciones farmaceuticas que lo contienen | |
| PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
| PE20090151A1 (es) | Derivados de pirimidinona y metodos para su uso | |
| CY1114927T1 (el) | Νεα 2-υποκατεστημενα παραγωγα μεθυλο πεναμης | |
| NO20074071L (no) | Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler | |
| AR066144A1 (es) | Derivados de aril pirrolidinas utiles como insecticidas y/o acaricidas y composiciones insecticidas que los contienen. | |
| CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
| AR035548A1 (es) | Compuestos organicos | |
| MY119238A (en) | 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| ECSP034611A (es) | Aminotiazoles y su uso como antagonistas del receptor de adenosina | |
| AR071644A1 (es) | Plaguicidas mesoionicos | |
| CO6190626A2 (es) | Compuestos y composiciones como inhibidores de proteasa activadora de canal | |
| DOP2011000061A (es) | Compuestos de pirrol | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| PE20090216A1 (es) | Compuestos triazolil aminopirimidina | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |